Petiq Intrinsic Value Calculator – PETIQ Reports Record-Breaking Earnings for Second Quarter of Fiscal Year 2023
August 17, 2023
🌥️Earnings Overview
On June 30, 2023, PETIQ ($NASDAQ:PETQ) announced their financial results for the second quarter of 2023, reporting total revenue of USD 314.6 million, a 24.8% increase from the same period of the previous year. Net income also grew by 104.5%, amounting to USD 9.5 million.
Market Price
On Tuesday, PETIQ, a leading provider of pet health and wellness products, reported record-breaking earnings for the second quarter of fiscal year 2023. The company’s stock opened at $17.1, and closed at $17.4, up by 1.0% from the prior closing price of 17.2. This marks a significant milestone for the company, as it continues to experience strong growth and increasing demand for its products. The impressive results were driven by a combination of increased sales of existing products, strong promotional campaigns, and the launch of new product lines. PETIQ was able to capitalize on the growing trend of pet owners seeking high-quality health and wellness products for their pets.
The company’s focus on customer service and innovation has been instrumental in driving positive earnings, and PETIQ expects the momentum to continue in the coming quarters. PETIQ’s optimism is shared by analysts, who predict that the company is well-positioned to capitalize on the long-term growth trend in the pet health and wellness industry. With a strong track record of success, PETIQ is confident that its future performance will once again exceed expectations. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Petiq. More…
| Total Revenues | Net Income | Net Margin |
| 998.82 | -36.8 | -0.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Petiq. More…
| Operations | Investing | Financing |
| 127.81 | -35.71 | -18.99 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Petiq. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 883.47 | 647.87 | 8.01 |
Key Ratios Snapshot
Some of the financial key ratios for Petiq are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.9% | 86.4% | -0.3% |
| FCF Margin | ROE | ROA |
| 12.0% | -1.0% | -0.2% |
Analysis – Petiq Intrinsic Value Calculator
At GoodWhale, we have conducted a financial analysis of PETIQ and have come to the conclusion that the intrinsic value of PETIQ share is around $24.1. This value was determined by our proprietary Valuation Line, which builds upon the discounted cash flow model. Investors should take note that the current traded price of PETIQ stock is $17.4, presenting an attractive opportunity for 27.9% upside potential. We believe that PETIQ is undervalued at the current price, offering good prospects for long-term investors. More…
Peers
The pet industry is a competitive one, with many companies vying for a share of the market. PetIQ Inc is one such company, and it competes with China Health Industries Holdings Inc, Healthy Extracts Inc, and BioGaia AB, among others.
– China Health Industries Holdings Inc ($OTCPK:CHHE)
The company’s market cap is 12.19M as of 2022, a Return on Equity of -0.5%. The company focuses on the development, manufacture and sale of health products in China.
– Healthy Extracts Inc ($OTCPK:HYEX)
Healthy Extracts Inc is a company that produces and sells health supplements. The company has a market cap of 17.93M as of 2022 and a Return on Equity of -25.8%. The company’s products are designed to improve the health and well-being of its customers.
– BioGaia AB ($LTS:0GTN)
BioGaia is a Swedish pharmaceutical company that focuses on developing and commercializing probiotics. The company’s products are based on lactic acid bacteria, which are found in the human body and are known to have numerous health benefits. Probiotics are live microorganisms that, when consumed in adequate amounts, can confer a health benefit on the host. BioGaia’s products are available in over 90 countries and are sold in a variety of formats, including capsules, tablets, liquids, and powders.
BioGaia’s market cap is 8.71B as of 2022. The company has a Return on Equity of 12.29%. BioGaia’s products are based on lactic acid bacteria, which are found in the human body and are known to have numerous health benefits. Probiotics are live microorganisms that, when consumed in adequate amounts, can confer a health benefit on the host.
Summary
PETIQ is a company worth investing in. In the second quarter of 2023, the company reported a 24.8% increase in total revenue from the same period in the previous year, and a 104.5% increase in net income. This impressive growth suggests that PETIQ is well-positioned to continue to see strong performance in the near future. Investors may be interested in this stock given its potential for strong returns.
Related Posts
Recent Posts
